<DOC>
	<DOC>NCT00220324</DOC>
	<brief_summary>The purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of SH D00342A. Subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.</brief_summary>
	<brief_title>Pearl Index Study With Low Dose Combined Oral Contraceptive</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Healthy women requiring contraception Pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Contraception</keyword>
</DOC>